Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cholangiocarcinoma Recurrent: early-phase trial registry
1 of 2 indexed Cholangiocarcinoma Recurrent trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Cholangiocarcinoma Recurrent: 2 US clinical trials tracked, 1 recruiting.
Cholangiocarcinoma Recurrent is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is TCR2 Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition cholangiocarcinoma-recurrent
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Cholangiocarcinoma Recurrent lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cholangiocarcinoma Recurrent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cholangiocarcinoma Recurrent is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
NCT05568680
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT03907852
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Cholangiocarcinoma Recurrent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cholangiocarcinoma Recurrent trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cholangiocarcinoma Recurrent page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Cholangiocarcinoma Recurrent trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- TCR2 Therapeutics sponsors the most Cholangiocarcinoma Recurrent trials on record, review their full trial history before evaluating a specific study. See TCR2 Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cholangiocarcinoma Recurrent condition card totals 2 registered trials; most-linked intervention gavo-cel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.